Literature DB >> 2969755

Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites.

M Laruelle1, M A Vanisberg, J M Maloteaux.   

Abstract

The characteristics of the binding of [3H]paroxetine, a selective serotonin (5-HT) uptake blocker, were investigated in human brain. The Kd value was 0.23 +/- 0.07 nM, and the Bmax value was 190 +/- 39 fmol/mg protein in the putamen. The capacity of various antidepressive drugs to inhibit [3H]paroxetine-specific binding in human brain was well correlated with their capacity to inhibit [3H]5-HT uptake in rat brain. The highest concentrations of [3H]paroxetine-specific binding sites were found in the substantia nigra, hypothalamus, and hippocampus. Lower values were obtained in the basal ganglia and the thalamus. The specific binding was very low in cerebral and cerebellar cortices. The regional distribution of [3H]paroxetine binding sites differs from that of [3H]ketanserin binding to S2 serotonin receptors. The subcellular distribution of the [3H]paroxetine-specific binding sites obtained by differential centrifugation revealed a synaptosomal enrichment in the frontal cortex and striatum, whereas an enrichment in the microsomal fraction was found in striatum. The results show that [3H]paroxetine is a ligand of choice to label the 5-HT uptake molecular complex in human brain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969755     DOI: 10.1016/0006-3223(88)90198-9

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  34 in total

1.  Dopamine and serotonin transporter availability in chronic heroin users: a [¹²³I]β-CIT SPECT imaging study.

Authors:  Kelly P Cosgrove; Karen Tellez-Jacques; Brian Pittman; Ismene Petrakis; Ronald M Baldwin; Gilles Tamagnan; John Seibyl; Thomas Kosten; Julie K Staley
Journal:  Psychiatry Res       Date:  2010-11-03       Impact factor: 3.222

2.  Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics.

Authors:  Martin A Javors; Chamindi Seneviratne; John D Roache; Nassima Ait-Daoud; Susan E Bergeson; M Consuelo Walss-Bass; Fatema Z Akhtar; Bankole A Johnson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-11-04       Impact factor: 5.067

3.  Differences between males and females in rates of serotonin synthesis in human brain.

Authors:  S Nishizawa; C Benkelfat; S N Young; M Leyton; S Mzengeza; C de Montigny; P Blier; M Diksic
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

4.  Lower 3H-paroxetine binding in cerebral cortex of suicide victims is partly due to fewer high affinity, non-transporter sites.

Authors:  J J Mann; R A Henteleff; T F Lagattuta; J A Perper; S Li; V Arango
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  Light therapy and serotonin transporter binding in the anterior cingulate and prefrontal cortex.

Authors:  S J Harrison; A E Tyrer; R D Levitan; X Xu; S Houle; A A Wilson; J N Nobrega; P M Rusjan; J H Meyer
Journal:  Acta Psychiatr Scand       Date:  2015-04-17       Impact factor: 6.392

6.  Evaluation of the agonist PET radioligand [¹¹C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242.

Authors:  Mika Naganawa; Leslie K Jacobsen; Ming-Qiang Zheng; Shu-Fei Lin; Anindita Banerjee; Wonkyung Byon; David Weinzimmer; Giampaolo Tomasi; Nabeel Nabulsi; Sarah Grimwood; Lori L Badura; Richard E Carson; Timothy J McCarthy; Yiyun Huang
Journal:  Neuroimage       Date:  2014-05-17       Impact factor: 6.556

7.  Architectonic distribution of the serotonin transporter within the orbitofrontal cortex of the vervet monkey.

Authors:  B M Way; G Laćan; L A Fairbanks; W P Melega
Journal:  Neuroscience       Date:  2007-07-17       Impact factor: 3.590

8.  Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls.

Authors:  Walter Koch; Marcus Unterrainer; Guoming Xiong; Peter Bartenstein; Markus Diemling; Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Morten Ziebell; Jacques Darcourt; Flavio Nobili; Marco Pagani; Swen Hesse; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-08       Impact factor: 9.236

9.  Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender.

Authors:  Henricus G Ruhé; Jan Booij; Johannes B Reitsma; Aart H Schene
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-30       Impact factor: 9.236

Review 10.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.